The Latin America, Middle East and Africa HIV Injection Market would witness market growth of 19.8% CAGR during the forecast period (2023-2030).
The Brazil market dominated the LAMEA HIV Injection Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $52.8 Million by 2029. The Argentina market is showcasing a CAGR of 20.7% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 19.4% during (2023 - 2030).
Studies have shown that adherence to oral antiretroviral therapy can be challenging for some patients, leading to suboptimal treatment outcomes and an increased risk of developing drug resistance. Injectable treatments, by contrast, are administered by healthcare providers, which can help ensure that patients receive their medications as prescribed. This can be especially important for patients who may struggle with adherence or who may be at risk of forgetting to take their medications.
The development of new antiretroviral drugs and treatment regimens has expanded the options available for injectable treatments, providing patients with more effective and convenient treatment options. One of the key advancements in HIV treatment has been the development of long-acting injectable therapies. These medications are administered less frequently than traditional oral medications, ranging from once a week to once every few months, depending on the specific drug.
Sub-Saharan Africa is classified as the region with the highest prevalence rates of HIV/AIDS on a global scale, with certain countries within the area bearing the brunt of this burden. For example, countries in southern Africa, such as South Africa, Swaziland, and Lesotho, have among the highest prevalence rates in the world. Hence, all of these factors will significantly support the expansion of the market in this region.
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA HIV Injection Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $52.8 Million by 2029. The Argentina market is showcasing a CAGR of 20.7% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 19.4% during (2023 - 2030).
Studies have shown that adherence to oral antiretroviral therapy can be challenging for some patients, leading to suboptimal treatment outcomes and an increased risk of developing drug resistance. Injectable treatments, by contrast, are administered by healthcare providers, which can help ensure that patients receive their medications as prescribed. This can be especially important for patients who may struggle with adherence or who may be at risk of forgetting to take their medications.
The development of new antiretroviral drugs and treatment regimens has expanded the options available for injectable treatments, providing patients with more effective and convenient treatment options. One of the key advancements in HIV treatment has been the development of long-acting injectable therapies. These medications are administered less frequently than traditional oral medications, ranging from once a week to once every few months, depending on the specific drug.
Sub-Saharan Africa is classified as the region with the highest prevalence rates of HIV/AIDS on a global scale, with certain countries within the area bearing the brunt of this burden. For example, countries in southern Africa, such as South Africa, Swaziland, and Lesotho, have among the highest prevalence rates in the world. Hence, all of these factors will significantly support the expansion of the market in this region.
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- GlaxoSmithKline PLC (GSK)
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F.Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie, Inc.
- Brii Biosciences Limited
- Shionogi & Co., Ltd.
- Boehringer Ingelheim International GmbH
Market Report Segmentation
By Distribution Channel- Hospital Pharmacy
- Drugs Stores & Retail Pharmacies
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA HIV Injection Market by Distribution Channel
Chapter 5. LAMEA HIV Injection Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F. Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie, Inc.
- Brii Biosciences Limited
- Shionogi & Co., Ltd.
- Boehringer Ingelheim International GmbH
Methodology
LOADING...
